ClinicalTrials.gg
CompletedNCT06775834Updated Sep 10, 2025

Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function

A Phase 1 interventional study of HRS-1893 in Hypertrophic Cardiomyopathy, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Cardiomyopathy, Hypertrophic with a site in China — 30 open to participants now, 43 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · China.

Enrollment
33rd of 39
24 · median 84
Started
2025
with 10 others
Phase 1
5 of 71
none open now
Registered
52nd of 71
by date
Lead sponsor
7 of 71
Shandong Suncadia Medicine Co., Ltd.

Among the 71 studies in Cardiomyopathy, Hypertrophic with a site in China, this one is the 33rd largest by enrollment of the 39 interventional ones that give a count, is one of 11 that started in 2025, is one of 5 in phase 1, and was the 52nd registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

30 of the 71 studies in Cardiomyopathy, Hypertrophic with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Cardiomyopathy, Hypertrophic with a site in China, or all of them as a file.
02

Study summary

The primary objective is to evaluate pharmacokinetics of HRS-1893 tablets in subjects with impaired kidney function in comparison with healthy subjects, to develop dose recommendations for patients with renal impairment.

03

Conditions studied

  • Hypertrophic Cardiomyopathy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign the before the trial, and fully understand the content, process and possible adverse reactions of the trial;
  2. Male or female subjects aged 18 to 65 (including 18 and 65);
  3. (BMI) ranges from 19 kg/m2 to 28 kg/m2 (including 18 and 28);
  4. The should meet the following criteria (GFR, mL/min): Subjects with mild renal impairment: 60-89 mL/min; Subjects with moderate renal impairment: 30-59 mL/min.

Exclusion criteria

Exclusion Criteria:

  1. Suspected allergy to the study drug or any component of the study drug;
  2. Patients with cardiogenic shock, severe conduction block, sick sinus syndrome, heart failure, sustained tachyarrhythmia, torsades de pointes (Tdp) or ventricular tachycardia, history of T wave changes, myocardial infarction, angina pectoris;
  3. People with conditions associated with reduced neuromuscular transmission (myasthenia gravis, Lambert-Eaton syndrome, Duchenne muscular dystrophy);
  4. Patients with a history of gastric or intestinal surgery that may affect drug absorption;
  5. Participants with renal insufficiency who were judged by the investigator to be ineligible for the study;
  6. Patients with large fluctuations or rapid deterioration of renal function within 2 weeks before administration, as judged by the investigator;
  7. Subjects receiving renal replacement therapy within 3 months of the screening period or during the expected trial period;
  8. Within 3 months before screening, patients with underlying diseases that induced chronic kidney disease and were poorly controlled according to the investigator's evaluation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Normal Renal Function Group

    Drug: HRS-1893

  • Experimental
    Mild Renal Impairment Group

    Drug: HRS-1893

  • Experimental
    Moderate Renal Impairment Group

    Drug: HRS-1893

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax)

    Time frame: 0 hour to 16 days after the dosing.

  2. Area under the plasma concentration-time curve from time zero to the time of last quantifiable analyte concentration (AUC0-t)

    Time frame: 0 hour to 16 days after the dosing.

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-∞)

    Time frame: 0 hour to 16 days after the dosing.

Secondary outcomes

  1. Time to reach maximum plasma concentration (Tmax)

    Time frame: 0 hour to 16 days after the dosing.

  2. Terminal half-life (t1/2)

    Time frame: 0 hour to 16 days after the dosing.

  3. Apparent clearance (CL/F)

    Time frame: 0 hour to 16 days after the dosing.

  4. Apparent volume of distribution (Vz/F)

    Time frame: 0 hour to 16 days after the dosing.

  5. Cumulative excretion (Ae)

    Time frame: 0 hour to 16 days after the dosing.

  6. Plasma protein binding rate (PPB)

    Time frame: 0 hour to 16 days after the dosing.

  7. Incidence and severity of adverse events (AEs)

    Time frame: 0 hour to 16 days after the dosing.

07

Study locations

1 site
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610072, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Jul 2025, 5 months.

Of 12 phase 1 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 5 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2025
First posted
Jan 15, 2025
StartActual
Feb 11, 2025
Primary completionActual
Jul 23, 2025
CompletionActual
Jul 23, 2025
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06775834
Responsible party
Sponsor
First posted
Jan 15, 2025
Start date
Feb 11, 2025
Primary completion
Jul 23, 2025
Completion
Jul 23, 2025
Last update
Sep 10, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-1893

Start the discussion